Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Fate Of Tiller's Clinic Expected To Be Decided This Week
The family of murdered Kansas abortion provider George Tiller is expected to decide this week whether his Wichita clinic will reopen, NPR"s "Morning Edition" reports. Tiller"s clinic is one of the few in the U.S. that performs abortions later in pregnancy, and many abortion-rights advocates are concerned whether women in need of abortions in the second and third trimester would be able to obtain care if it were not reopened. LeRoy Carhart, a Nebraska abortion provider who worked with Tiller at his clinic for four years, said that although it is a difficult time for abortion providers, he hopes that the family will reopen the clinic. "This is a job that we took, and we were well-aware of the risks when we started, as was Dr. Tiller," he said. Providing abortion services in the second and third trimester is "a service that"s so needed that it"s worth the risks," he added (Lohr, "Morning Edition," NPR, 6/9). Carhart also said that although no decision on Tiller"s clinic has been made, he "want[s] to assure the press and the women of America ... that we will somehow, somewhere continue to provide abortions later in gestation" (Duin, Washington Times, 6/9).According to Carhart, there are only about 10 providers in the U.S. who perform abortions in the second and third trimesters, including a few hospitals that do not advertise the services. "Morning Edition" reports that most women"s health care providers either are not trained or do not want to receive training to perform the procedure later in pregnancy. Providers who do tend to be older and face extreme pressure from antiabortion-rights advocates. Data from the Guttmacher Institute show that about 1% of all abortions performed in the U.S. occur after 21 weeks" gestation. Elizabeth Nash of Guttmacher said that 37 states have laws that limit access to abortion after a certain point in pregnancy, "usually around 24 weeks, which is at the end of the second trimester." She added that most of those states only allow abortions to save the life of the woman or if her physical health is in jeopardy. Pratima Gupta, an ob-gyn in California, said that she is concerned about what will happen to Tiller"s patients. Gupta said Tiller "had patients that were scheduled for Monday morning. What happened to those patients for the rest of the week, the rest of the month? Those patients are the ones who need us" ("Morning Edition," NPR, 6/9).
generic viagra online
Evaluating More Lymph Nodes May Not Improve Identification Of Late-Stage Colorectal Cancer
Surgically removing and evaluating an increasing number of lymph nodes does not appear to identify a greater number of patients with stage III colorectal cancer, according to a report in the July issue of Archives of Surgery, one of the JAMA/Archives journals.
News of the day
Advances In Nutritional Support For The Hospitalized Patient
WHAT:
Endocrinology

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis. HYLATOPIC™ Emollient Foam is formulated to rapidly hydrate the stratum corneum, the top layer of the skin, and immediately provide a semi-permeable barrier that protects against irritants and excessive water loss through the epidermis. HYLATOPIC™ is clinically proven to rapidly increase skin hydration and reduce transepidermal water loss1, supporting the skin"s natural recovery from skin barrier dysfunction to optimize therapeutic outcomes. HYLATOPIC™ is safe and easy to spread over large areas and therefore is ideal for atopic dermatitis patients with disease coverage on greater than 10% body surface area (BSA). The Company"s recent market research with dermatologists indicates that 70% or more of their patients may have atopic dermatitis present on at least 10% of their body. Developed with the Company"s DELEVO™ Foam Technology, HYLATOPIC™ is cosmetically elegant, contains no drying alcohols, is absorbed rapidly, and leaves no oily or sticky residue. "We are very excited to be able to offer HYLATOPIC™ to our physicians and patients," states Michael Heffernan, President of Onset Therapeutics. "It is well known that skin barrier dysfunction is a fundamental problem in atopic dermatitis patients. HYLATOPIC"s 3-step approach to hydrate, protect and restore the natural skin barrier, combined with the aesthetic and safety elements which drive compliance, assists in helping our physicians achieve the best therapeutic outcomes." HYLATOPIC™ Emollient Foam is currently available through all major drug wholesalers. About Atopic Dermatitis Atopic dermatitis is a disease characterized by dry, cracked, itchy, and inflamed skin, often presenting on greater than 10% of the body surface area. It accounts for 10-20% of all Dermatology visits2 and affects approximately 3% of the US population2, 90% of whom develop symptoms by age 53. The compromised skin barrier in atopic dermatitis patients allows excessive water loss through the epidermal layer of the skin and penetration of potential allergens. About Onset Therapeutics Onset Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of dermatology products formulated with the Company"s innovative proprietary topical formulation technologies and unique delivery systems. The Company utilizes its novel DELEVO™ Foam Technology that is designed to deliver enhanced penetration of proven active ingredients in cosmetically elegant, hydrating formulations with the goal of enhancing patient compliance. For more information, please visit the company"s website at http://www.onsettx.com. References: 1. Data on File Collegium Pharmaceutical 2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Available at: http://www.niams.nih.gov/hi/topics/dermatitis/index.html. 3. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721. Onset Therapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009